NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-NS-19-044 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-037 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-19-015 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs). This FOA seeks to promote critical target validation approaches to help de-risk subsequent translational research and accelerate the advancement of novel therapies for ADRD. Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples. In its initial phase, this FOA provided support for up to two years (UG3 stage) for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidate(s) in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. Upon demonstration of technical feasibilities, a second phase (UH3 stage) will carefully and reproducibly measure and cross-validate the impact of the target modulation in different modalities across collaborating laboratories using the NIH rigor and reproducibility guidelines. Applicants responding to this FOA must address objectives for both the UG3 and UH3 phases and are expected to have a substantial collaborative effort between independents laboratories. This FOA is not specific for any one or group within the ADRD spectrum of disorders. Disorders covered in these applications are frontotemporal degeneration (FTD), Lewy body dementias (LBD) (including dementia with Lewy bodies (DLB)), Parkinson disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), mixed dementias including the associated diagnostic challenges of multiples etiology dementias (MED).
Notice NOT-EY-19-019 from the NIH Guide for Grants and Contracts
Notice NOT-HG-19-017 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-007 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-028 from the NIH Guide for Grants and Contracts
Notice NOT-HS-19-012 from the NIH Guide for Grants and Contracts
Notice NOT-HD-19-005 from the NIH Guide for Grants and Contracts
Notice NOT-FD-19-007 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-19-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish a coordinated network of Emerging Infectious Disease Research Centers (EIDRCs) in regions around the globe where emerging and re-emerging infectious disease outbreaks are likely to occur. Multidisciplinary teams of investigators will conduct pathogen/host surveillance, study pathogen transmission, pathogenesis and immunologic responses in the host, and will develop reagents and diagnostic assays for improved detection for important emerging pathogens and their vectors.
Notice NOT-EY-19-014 from the NIH Guide for Grants and Contracts
Notice NOT-EY-19-013 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-20-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications proposing research on the specific role of aging biology in the development, etiology and treatment of Alzheimer's disease. Aging is by far the main risk factor for most chronic diseases, a fact recognized by the field of geroscience. Recent advances in the fields of basic aging biology and geroscience now allow researchers to address mechanistically the role of aging in Alzheimers disease. Applications that make use of geroscience principles and test the role of different hallmarks of aging biology are specifically appropriate, while those focused solely on aging biology, or solely on Alzheimers disease will be deemed unresponsive to the FOA.
Funding Opportunity RFA-AG-20-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications proposing research on the specific role of aging biology in the development, etiology and treatment of Alzheimer's disease. Aging is by far the main risk factor for most chronic diseases, a fact recognized by the field of geroscience. Recent advances in the fields of basic aging biology and geroscience now allow researchers to address mechanistically the role of aging in Alzheimers disease. Applications that make use of geroscience principles and test the role of different hallmarks of aging biology are specifically appropriate, while those focused solely on aging biology, or solely on Alzheimers disease will be deemed unresponsive to the FOA.
Notice NOT-EY-19-015 from the NIH Guide for Grants and Contracts
Notice NOT-EY-19-012 from the NIH Guide for Grants and Contracts
Notice NOT-HL-19-686 from the NIH Guide for Grants and Contracts
Notice NOT-EB-19-004 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-039 from the NIH Guide for Grants and Contracts